SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

JDQ443

Item No. 38157

CAS Registry No.:	2653994-08-0
Formal Name:	1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one
Synonym:	Opnurasib
MF:	$C_{29}H_{28}ClN_7O$
FW:	526.0
Purity:	≥98%
UV/Vis.:	λ_{max}: 242 nm
Supplied as:	A solid
Storage:	-20°C
Stability:	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

JDQ443 is supplied as a solid. A stock solution may be made by dissolving the JDQ443 in the solvent of choice, which should be purged with an inert gas. JDQ443 is soluble in the organic solvent DMSO.

Description

JDQ443 is a covalent inhibitor of K-Ras^{G12C}, a mutant form of K-Ras that accumulates in cancer cells.[1] It decreases K-Ras^{G12C}-induced phosphorylation of ERK in NCI H358 non-small cell lung cancer (NSCLC) cells (IC_{50} = 0.020 µM). JDQ443 selectively inhibits the growth of NCI H358 cells, which express K-Ras^{G12C}, over NCI H1437 NSCLC cells expressing wild-type K-Ras and the constitutively active mutant MEK^{Q56P} (GI_{50}s = 0.018 and 4.4 µM, respectively). It reduces blood levels of free K-Ras^{G12C} at three, six, and 24 hours in a MiaPaCa-2 pancreatic cancer mouse xenograft model when administered at a dose of 30 mg/kg and inhibits tumor growth and decreases tumor volume in the same model at 10 and 30 mg/kg per day.

Reference

1. Lorthiois, E., Gerspacher, M., Beyer, K.S., *et al.* JDQ443, a structurally novel, pyrazole-based, covalent inhibitor of KRAS^{G12C} for the treatment of solid tumors. *J. Med. Chem.* **65(24)**, 16173-16203 (2022).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM